Additional applications
Contrast-Associated AKI
(CA-AKI)
CA-AKI is caused by exposure to contrast media during image-guided cardiology and radiology procedures.
These image-guided medical procedures require the use of an iodine-based radio-contrast media, or dye, to facilitate the capture and display of x-ray images.
These contrast agents are known to be toxic to the kidney, whose main function is to filter and remove wastes and fluids from the body. The lack of effective treatment to prevent CA-AKI remains a huge challenge for patients with renal insufficiency.
RenalPro is designed to reduce the toxic effects that contrast media can have on the kidneys, which may lead to a reduction in the incidence of CA-AKI in at-risk patients.
A meta-analysis of 10 studies related to the use of RenalGuard in high-risk patients showed that RenalGuard was associated with more than a 50% risk reduction in CA-AKI compared to the control group. Furthermore, use of RenalGuard was associated with decreased mortality, dialysis, and major adverse cardiac events (MACCE) compared to the control.
Growing installed base
Included in treatment guidelines
CE approved
50% reduction in AKI
Our Publications
Multiple studies demonstrating our technology have been published in peer-reviewed journals.
ICU-AKI
More than 50% prevalence
in 8 million patients
AKI is a significant concern in ICUs, with a prevalence rate exceeding 50% among critically ill patients. This high incidence is primarily due to a complex interplay of factors such as sepsis, severe infections, and the use of nephrotoxic medications that are common in ICUs. Additionally, the administration of intravenous contrast agents for diagnostic purposes can exacerbate the risk of AKI, particularly in patients with pre-existing renal impairment.
There are about 7.8 million ICU patients each year in the US and Europe, a market opportunity of $7B.
There are about 7.8 million ICU patients each year in the US and Europe, a market opportunity of $7B.
CardioRenal System’s ICU AKI-prevention product in development focuses on effective hemodynamic management to mitigate the risk of AKI in critical care settings, after showing promise in a small scale clinical study. The company is preparing a larger proof-of-concept (PoC) trial to validate the efficacy of their approach, which currently relies on manual fluid management practices. This trial is set to pave the way for the potential integration of AI-enabled monitoring and treatment solutions.
Welcome to the World of
Automated Balanced Hydration
Before, During, and After Surgery.